﻿{"id":1276883,"date":"2018-08-29T23:00:43","date_gmt":"2018-08-29T20:00:43","guid":{"rendered":"http:\/\/www.erzurumflas.com\/biyobenzer-ilaclarin-ulke-ekonomisine-katkisi\/"},"modified":"2018-08-29T23:00:51","modified_gmt":"2018-08-29T20:00:51","slug":"biyobenzer-ilaclarin-ulke-ekonomisine-katkisi","status":"publish","type":"post","link":"https:\/\/www.erzhaber.com\/?p=1276883","title":{"rendered":"Biyobenzer ila\u00e7lar\u0131n \u00fclke ekonomisine katk\u0131s\u0131"},"content":{"rendered":"<p><img decoding=\"async\" src=\"http:\/\/www.erzurumflas.com\/wp-content\/uploads\/2018\/08\/biyobenzer-ilaclarin-ulke-ekonomisine-katkisi_527feaf.jpg\" width=\"600\">Biyobenzer ila\u00e7lar\u0131n yenilik\u00e7i tedavilerin \u00f6n\u00fcn\u00fc a\u00e7aca\u011f\u0131n\u0131 belirten TRPharm Y\u00f6netim Kurulu Ba\u015fkan\u0131 Mehmet G\u00f6ker, ila\u00e7lar\u0131n \u00fclke ekonomisine katk\u0131 sa\u011flad\u0131\u011f\u0131n\u0131 kaydetti.<\/p>\n<p>H\u00fck\u00fcmetin biyoteknolojik ila\u00e7larla ilgili Stratejik Te\u015fvik Belgesi firmalar\u0131 harekete ge\u00e7irdi. Kanser tedavilerinde yo\u011fun kullan\u0131lan baz\u0131 ila\u00e7lar\u0131n biyobenzerleri \u201cBedeli \u00f6denecek ila\u00e7lar listesine\u201d ve \u201cHastanelerce Temini Zorunlu Kemoterapi \u0130la\u00e7lar\u0131 Listesi\u201dne al\u0131nmas\u0131yla kanser hastalar\u0131n\u0131n tedavisini do\u011frudan \u00fcstlenen SGK\u2019n\u0131n b\u00fct\u00e7esine do\u011frudan 200 milyon lira civar\u0131nda katk\u0131s\u0131 olaca\u011f\u0131 belirtiliyor. S\u00f6z konusu biyobenzer ila\u00e7lar\u0131n sisteme al\u0131nmas\u0131yla ila\u00e7 ihalelerindeki fiyatlar\u0131n d\u00fc\u015f\u00fcr\u00fclmesini de sa\u011flayaca\u011f\u0131na dikkat \u00e7ekilerek, ihalelerde olu\u015facak iskontolarla birlikte toplam kamu tasarrufunun yakla\u015f\u0131k 300 milyon liray\u0131 bulmas\u0131n\u0131n beklendi\u011fi belirtiliyor.<\/p>\n<p>Tasarruf i\u00e7in 27 Eyl\u00fcl kritik g\u00fcn<\/p>\n<p>Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019n\u0131n 2019 ve 2020 y\u0131llar\u0131ndaki ila\u00e7 al\u0131mlar\u0131na y\u00f6nelik olarak \u00f6n\u00fcm\u00fczdeki 27 Eyl\u00fcl tarihinde yapaca\u011f\u0131 ila\u00e7 al\u0131m ihalesi kapsam\u0131nda, var olan orijinal ila\u00e7lar i\u00e7in olu\u015facak kamu maliyeti 622.2 milyon liraya kadar \u00e7\u0131kacak. Bu ila\u00e7lar\u0131n biyobenzerleri geri \u00f6deme listesine al\u0131nma s\u00fcrecinin \u00f6n\u00fcm\u00fczdeki 27 Eyl\u00fcl tarihine kadar tamamlanm\u0131\u015f olmas\u0131 durumunda ise bu tutar 445.4 milyon liraya gerileyecek.<\/p>\n<p>\u201cYenilik\u00e7i tedavilerin yolunu a\u00e7acakt\u0131r\u201d<\/p>\n<p>Kimyasal bile\u015fimler yerine, biyolojik y\u00f6ntemlerle organizmalardan ve canl\u0131 sistemlerden \u00fcretilen biyoteknolojik \u00fcr\u00fcnlerin e\u015fde\u011feri olan biyobenzer \u00fcr\u00fcn\u00fcn\u00fcn T\u00fcrkiye\u2019de hastalar\u0131n istifadesine sunuldu\u011funu belirten TRPharm Y\u00f6netim Kurulu Ba\u015fkan\u0131 Mehmet G\u00f6ker, \u201cBiyobenzer \u00fcr\u00fcnler yaln\u0131zca daha fazla hastan\u0131n bu \u00f6nemli tedavilere eri\u015fmesini sa\u011flamakla kalmay\u0131p, ayn\u0131 zamanda kullan\u0131ld\u0131klar\u0131 tedavi alanlar\u0131ndaki sa\u011fl\u0131k maliyetlerini d\u00fc\u015f\u00fcrerek, di\u011fer alanlarda yeni ve yenilik\u00e7i tedavilerin yolunu a\u00e7acakt\u0131r\u201d dedi.<\/p>\n<p>\u201cBiyobenzer \u00fcr\u00fcnler, \u00fclke ekonomisine fayda sa\u011flar&#8221;<\/p>\n<p>Biyobenzer ila\u00e7lar\u0131n, mevcut \u00fcr\u00fcnlere k\u0131yasla ayn\u0131 etkiye sahip olmakla birlikte daha ekonomik, bu \u00f6nemli bir avantaj oldu\u011funu s\u00f6yleyen G\u00f6ker, \u201cBunun yan\u0131 s\u0131ra biyobenzerlerin \u00fclkeye girmesiyle teknoloji transferi de sa\u011flanacak ve \u00fcretimin T\u00fcrkiye\u2019de yap\u0131lmas\u0131yla birlikte ihracat potansiyeli de artacak. B\u00f6ylece ithal \u00fcr\u00fcnlerden olu\u015fan T\u00fcrkiye ila\u00e7 pazar\u0131, ihracat yapan noktaya gelecek&#8221; diye konu\u015ftu.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>B\u0130YOBENZER \u0130LA\u00c7LARIN YEN\u0130L\u0130K\u00c7\u0130 TEDAV\u0130LER\u0130N \u00d6N\u00dcN\u00dc A\u00c7ACA\u011eINI BEL\u0130RTEN TRPHARM Y\u00d6NET\u0130M KURULU BA\u015eKANI MEHMET G\u00d6KER, \u0130LA\u00c7LARIN \u00dcLKE EKONOM\u0130S\u0130NE KATKI SA\u011eLADI\u011eINI KAYDETT\u0130.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14,20],"tags":[105698,21382,54383,20476,7462],"class_list":["post-1276883","post","type-post","status-publish","format-standard","hentry","category-saglik","category-turkiye","tag-biyobenzer","tag-ekonomisine","tag-ilaclarin","tag-katkisi","tag-ulke"],"_links":{"self":[{"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/posts\/1276883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1276883"}],"version-history":[{"count":0,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/posts\/1276883\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1276883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1276883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1276883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}